Home / Stock ratings / XLV
ETF rating
State Street Health Care Select Sector SPDR ETF (XLV) ETF Rating & Analysis
As of September 29, 2026, MELANY rates State Street Health Care Select Sector SPDR ETF 72 out of 100 (Sector Leader). Its highest factor score is cost and structure at 98, and its lowest is relative strength at 56.
MELANY ratingRated 2026-09-29XLV · composite score
About State Street Health Care Select Sector SPDR ETF
Health Care Select Sector SPDR Fund tracks health-care companies in the S&P 500 - pharmaceuticals, biotechnology, providers, and medical devices.
Rating as of 2026-09-29 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why XLV scores 72/100
XLV's 8 factor scores run from 56 to 98, and 3 of them sit above its composite of 72. Here is how XLV breaks down.
How well the fund spreads risk across holdings rather than concentrating it.
Expense ratio, size and how soundly the fund is built.
- Very low cost, 0.08% expense ratio
Direction and quality of the fund price trend.
- Uptrend confirmed, price and 50-day above the 200-day MA
Distribution yield and how dependable that income has been.
How the fund is performing against its peer group and the broad market.
Whether the current move looks durable or stretched.
Return weighed against volatility and drawdown.
How the current rate and market regime suits this kind of fund.
- Risk-on tape supports growth/cyclical exposure
Key risks for XLV
- No acute structural risks flagged, standard market risk applies
XLV trade plan (Pro)
MELANY has a full position plan for State Street Health Care Select Sector SPDR ETF: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates XLV
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. State Street Health Care Select Sector SPDR ETF's 72/100 reflects etf factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about XLV
Is State Street Health Care Select Sector SPDR ETF (XLV) a buy?
As of 2026-09-29, MELANY rated State Street Health Care Select Sector SPDR ETF Sector Leader with a composite score of 72/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is State Street Health Care Select Sector SPDR ETF's MELANY score?
State Street Health Care Select Sector SPDR ETF (XLV) has a MELANY composite score of 72/100, combining diversification, cost & structure, trend & structure, income, relative strength, momentum quality, risk-adj. return, regime fit.
How is the XLV ETF rating calculated?
MELANY scores XLV from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy State Street Health Care Select Sector SPDR ETF ETF?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates State Street Health Care Select Sector SPDR ETF (XLV) Sector Leader with a composite of 72/100 as of 2026-09-29. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the XLV ETF price forecast?
MELANY does not publish price targets or forecasts for XLV. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 72/100 across eight factors for State Street Health Care Select Sector SPDR ETF, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is XLV ETF overvalued or undervalued?
MELANY's diversification factor currently reads 57/100 for State Street Health Care Select Sector SPDR ETF, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives XLV's read.
What price should I buy XLV at?
Rather than chasing the current price, MELANY computes a smart entry zone for XLV: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying XLV ETF?
The top risks MELANY currently flags for State Street Health Care Select Sector SPDR ETF: No acute structural risks flagged, standard market risk applies. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is State Street Health Care Select Sector SPDR ETF a good long-term investment?
For long-term durability the two factors that matter most are cost & structure, which MELANY scores 98/100 for State Street Health Care Select Sector SPDR ETF, and income, at 66/100. The 72/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will XLV ETF go up?
Nobody can promise a fund's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's trend & structure factor reads 81/100 for XLV right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this XLV rating?
The rating on this page is a snapshot of MELANY's read as of 2026-09-29. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores XLV continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, XLV included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.